{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:04:49Z","timestamp":1793228689706,"version":"4.5.0"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,2,1]]},"DOI":"10.2169\/internalmedicine.5431-20","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T22:12:21Z","timestamp":1598652741000},"page":"391-396","source":"Crossref","is-referenced-by-count":18,"title":["The Development of Foveolar-type Gastric Adenocarcinoma during Maintenance Therapy of Vonoprazan for Reflux Esophagitis"],"prefix":"10.2169","volume":"60","author":[{"given":"Masahiro","family":"Saito","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"},{"name":"Tohoku University Tohoku Medical Megabank Organization, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Koike","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Abe","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kanno","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waku","family":"Hatta","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaname","family":"Uno","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Asano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Imatani","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyoshi","family":"Fujishima","sequence":"additional","affiliation":[{"name":"Division of Pathology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Masamune","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Yang X, Li Y, Sun Y, et al. Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci 63: 302-311, 2018."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Garnock-Jones KP. Vonoprazan: first global approval. Drugs 75: 439-443, 2015.","DOI":"10.1007\/s40265-015-0368-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study. Aliment Pharmacol Ther 42: 719-730, 2015.","DOI":"10.1111\/apt.13325"},{"key":"4","unstructured":"4. Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers -results from two phase 3, noninferiority randomised controlled trials. Aliment Pharmacol Ther 45: 240-252, 2017."},{"key":"5","unstructured":"5. Jung Y, Kim E, Park C. Systematic review with metaanalysis: the efficacy of vonoprazan-based trial therapy on <i>Helicobacter pylori<\/i> eradication. Aliment Pharmacol Ther 46: 106-114, 2017."},{"key":"6","unstructured":"6. Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassiumcompetitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 43: 240-251, 2016."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 43: 1048-1059, 2016.","DOI":"10.1111\/apt.13588"},{"key":"8","unstructured":"8. Lundell L, Vieth M, Gibson F, et al. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 42: 649-663, 2015."},{"key":"9","unstructured":"9. Uemura N, Kinoshita Y, Haruma K, et al. Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. Clin Exp Gastroenterol 11: 51-56, 2018."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hayakawa Y, Chang W, Jin G, et al. Gastrin and upper GI cancers. Curr Opin Pharmacol 31: 31-37, 2016.","DOI":"10.1016\/j.coph.2016.08.013"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Schmitz F, Goke MN, Otte JM, et al. Cellular expression of CCK-A and CCK-B\/gastrin receptors in human gastric mucosa. Regul Pept 102: 101-110, 2001.","DOI":"10.1016\/S0167-0115(01)00307-X"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guideline 2010: 3rd English edition. Gastric Cancer 14: 113-123, 2011.","DOI":"10.1007\/s10120-011-0042-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Shibagaki K, Fukuyama C, Mikami H, et al. Gastric foveolar-type adenomas endoscopically showing a raspberry-like appearance in the <i>Helicobacter pylori<\/i> -uninfected stomach. Endosc Int Open 7: E784-E791, 2019.","DOI":"10.1055\/a-0854-3818"},{"key":"14","unstructured":"14. Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 1: 23-32, 2015."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/3\/60_5431-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T05:49:05Z","timestamp":1612590545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/3\/60_5431-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5431-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}